EAG opens elemental impurities lab citing US FDA alignment efforts

By Gareth Macdonald

- Last updated on GMT

EAG opens elemental impurities lab citing US FDA alignment efforts
EAG Laboratories has set up an elemental impurities lab in response to US FDA moves to align testing rules with ICH Q3D guidance and USP requirements.

The lab - located at EAG’s facility in Columbia, Missouri - houses six inductively coupled plasma/mass spectrometry instruments, which will be used to test drug ingredients and excipients for metal impurities.

The firm cited recommendations published by the US Food and Drug Administration (FDA) in June​ in which the agency outlined its efforts to align testing rules with International Council for Harmonisation (ICH) guidance and United States Pharmacopeia (USP) requirements.

The regulations – which come into effect in January 2018 – require that manufacturers of brand-name, generic and over-the-counter drugs

Elemental impurities are traces of metals that present in drug formulations as a result of the production process. The impurities can be harmful to patients, which is why regulators require that that drug firms measure and control for their presence.

EAG did not respond to a request for comment.

Combination

EAG recently​ combined 11 of its brands, including ABC Laboratories, to reside under a single company.

As this publication previously reported​, the company has been expanding it capabilities to further support the biopharmaceutical market.

Siddhartha Kadia, EAG Laboratories president and CEO told us the life science market is a “key growth engine​” for the company and that it will continue to invest, both organically and additively, in areas that complement the company’s offerings.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars